Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The Digital Innovation business performed well in the web-based examination delivery platform, insider threat protection solutions, proprietary AI services and application development, driven by an increase in platform users. The ICT business reported higher revenue from orders for spot projects, but lower income due to the loss of high-margin projects. The Life Sciences business reported higher revenue and income as a result of growth in medical equipment maintenance and consulting, the acquisition of high-margin projects, and optimized staffing.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥9,897 million (YoY +7.4%) |
| Operating profit | ¥963 million (YoY +17.4%) |
| Ordinary income | ¥980 million (YoY +18.3%) |
| Profit attributable to owners of the parent | ¥686 million (YoY +22.0%) |
| Net income per share | ¥120.65 |
| Operating Margin | 9.7% |
| Equity ratio | End of the current fiscal period 61.7% / End of previous period 61.8% |
| Total assets | ¥6,565 million |
| Net assets | ¥4,048 million |
| Cash flows from operating activities | ¥733 million |
| Cash flows from investing activities | ¥-100 million |
| Cash flows from financing activities | ¥-325 million |
| Cash and cash equivalents at end of period | ¥3,598 million |
| Full-year earnings forecast | Net Sales ¥10,000 million (YoY +1.0%) / Operating profit ¥1,000 million (YoY +3.8%) / Ordinary income ¥1,000 million (YoY +2.0%) / Net income ¥700 million (YoY +2.0%) |
| Annual Dividend Forecast | ¥49 per share → ¥50 per share（+2.0%） |
| Payout ratio | 40.6% (fiscal year ended March 2026) |
| Shareholder Return Policy | The higher of annual dividends of ¥25 per share or a payout ratio of at least 40% |
| Segment revenue | Digital Innovation business ¥2,666,089 thousand (YoY +19.1%), ICT business ¥5,225,088 thousand (YoY +4.1%), Life Sciences Business ¥1,947,714 thousand (YoY +1.3%), Other ¥58,138 thousand (YoY +71.6%) |
| Segment profit | Digital Innovation business ¥310,636 thousand (YoY +72.8%), ICT business ¥1,147,549 thousand (YoY -7.0%), Life Sciences Business ¥355,231 thousand (YoY +27.1%), Other ¥-141 thousand |
| Depreciation and amortization | ¥55,364 thousand |
| Impairment loss | ¥48,660 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥48,660 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Acquisition of treasury shares. The Company acquired 63,000 shares between 1 April and 30 April 2026 for a total acquisition cost of ¥76,902,100. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (対象者：Not disclosed) |
| Issued Shares at Period-End | 6,015,600 shares |
| Treasury Shares at Period-End | 395,032 shares |
| Factors Behind Changes in Business Performance | The Digital Innovation business performed well in the web-based examination delivery platform, insider threat protection solutions, proprietary AI services and application development, driven by an increase in platform users. The ICT business reported higher revenue from orders for spot projects, but lower income due to the loss of high-margin projects. The Life Sciences business reported higher revenue and income as a result of growth in medical equipment maintenance and consulting, the acquisition of high-margin projects, and optimized staffing. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company expanded the release of its proprietary solutions in the AI, Data and Security technology domains, recruitment and training of engineers and consultants, and investment in sales and marketing. The Digital Innovation and Life Sciences businesses grew, while the ICT business reported lower income due partly to the loss of high-margin projects.